Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05722418 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05722418 · ClinicalTrials.gov record · last posted 2025-09-25

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Study acronym: CaMMouflage
StatusRecruiting
PhasePhase 1
Started2023-02-06
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).

Amendment record 23 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 23 times since 2023-02-02; most recent amendment 2025-09-23. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-02-10
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT05722418
Lead Sponsor Caribou Biosciences, Inc.
Conditions Relapsed/Refractory Multiple Myeloma
Enrollment 50 participants
Start Date 2023-02-06
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-25